Advertisement

Picture Campus Berlin-Buch GmbH CBB Location of Future Innovation 650x100px
Collaboration › Details

Merck (DE)–NMS Group: PARP inhibitor, 202209– collab + license option for PARP1 selective inhibitor NMS-293

 

Period Period 2022-09-21
Region Region ALL
Organisations Partner, 1st Merck KGaA
  Group Merck (DE) (Group)
  Partner, 2nd Nerviano Medical Sciences S.r.l. (NMS Srl)
  Group NMS Group (Group)
Products Product NMS-293 (NMS Group / Merck (DE))
  Product 2 drug development
Person Person Zazulina, Victoria (Merck (DE) 202209 Head of Development Unit Oncology before Boehringer Ingelheim)
Document Source Merck KGaA. (9/21/22). "Press Release: Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor [ Not intended for US- or Canada- and UK-based media ]". Darmstadt.
     

   
Record changed: 2022-11-19

Advertisement

Picture [iito] No Content Marketing 650x100px

More documents for Merck (DE) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group Biotech Showcase 2023 San Francisco 650x300px




» top